UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 28, 2020
OR
TRANSITION REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _______ to _______
COMMISSION FILE NUMBER 1-3619
----
PFIZER INC.
(Exact name of registrant as specified in its charter)
Delaware
13-5315170
(State of Incorporation)
(I.R.S. Employer Identification No.)
235 East 42nd Street, New York, New York 10017
(Address of principal executive offices) (zip code)
(212) 733-2323
(Registrant s telephone number)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $.05 par value
PFE
New York Stock Exchange
0.250% Notes due 2022
PFE22
New York Stock Exchange
1.000% Notes due 2027
PFE27
New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes
No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes
No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act:
Large Accelerated filer x Accelerated filer Non-accelerated filer Smaller reporting company Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes
No
At August 3, 2020, 5,556,879,807 shares of the issuer s voting common stock were outstanding.
Table of Contents
PART I. FINANCIAL INFORMATION
Page
Item 1.
Financial Statements
Condensed Consolidated Statements of Income for the three and six months ended June 28, 2020 and June 30, 2019
Condensed Consolidated Statements of Comprehensive Income for the three and six months ended June 28, 2020 and June 30, 2019
Condensed Consolidated Balance Sheets as of June 28, 2020 and December 31, 2019
Condensed Consolidated Statements of Equity for the three and six months ended June 28, 2020 and June 30, 2019
Condensed Consolidated Statements of Cash Flows for the six months ended June 28, 2020 and June 30, 2019
10
Notes to Condensed Consolidated Financial Statements
11
Report of Independent Registered Public Accounting Firm
45
Item 2.
Management s Discussion and Analysis of Financial Condition and Results of Operations
46
Item 3.
Quantitative and Qualitative Disclosures About Market Risk
98
Item 4.
Controls and Procedures
98
PART II. OTHER INFORMATION
Item 1.
Legal Proceedings
98
Item 1A.
Risk Factors
98
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
100
Item 3.
Defaults Upon Senior Securities
100
Item 4.
Mine Safety Disclosures
100
Item 5.
Other Information
100
Item 6.
Exhibits
101
Signature
102
GLOSSARY OF DEFINED TERMS
Unless the context requires otherwise, references to Pfizer, the Company, we, us or our in this Quarterly Report on Form 10-Q (defined below) refer to Pfizer Inc. and its subsidiaries. We also have used several other terms in this Quarterly Report on Form 10-Q, most of which are explained or defined below:
2019 Financial Report
Financial Report for the fiscal year ended December 31, 2019, which was filed as Exhibit 13 to the Annual Report on Form 10-K for the fiscal year ended December 31, 2019
2019 Form 10-K
Annual Report on Form 10-K for the fiscal year ended December 31, 2019
ACA (Also referred to as U.S. Healthcare Legislation)
U.S. Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act
ACIP
Advisory Committee on Immunization Practices
ALK
anaplastic lymphoma kinase
Alliance revenues
Revenues from alliance agreements under which we co-promote products discovered or developed by other companies or us
Allogene
Allogene Therapeutics, Inc.
AML
Acute Myeloid Leukemia
Anacor
Anacor Pharmaceuticals, Inc.
Array
Array BioPharma Inc.
Astellas
Astellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc.
ATTR-CM
transthyretin amyloid cardiomyopathy
Bamboo
Bamboo Therapeutics, Inc.
BioNTech
BioNTech SE
Biopharma
Pfizer Biopharmaceuticals Group
BMS
Bristol-Myers Squibb Company
CDC
U.S. Centers for Disease Control and Prevention
cGMP
current Good Manufacturing Practices
COVID-19
novel coronavirus disease of 2019
Developed Markets
U.S., Western Europe, Japan, Canada, South Korea, Australia, Scandinavian countries, Finland and
New Zealand
EMA
European Medicines Agency
Emerging Markets
Includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea),
Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey
EPS
earnings per share
EU
European Union
Exchange Act
Securities Exchange Act of 1934, as amended
FASB
Financial Accounting Standards Board
FDA
U.S. Food and Drug Administration
GAAP
Generally Accepted Accounting Principles
GIST
gastrointestinal stromal tumors
GPD
Global Product Development organization
GSK
GlaxoSmithKline plc
hGH-CTP
human growth hormone
Hospira
Hospira, Inc.
IBT
Income before tax
ICU Medical
ICU Medical, Inc.
IPR&D
in-process research and development
IRS
U.S. Internal Revenue Service
IV
intravenous
J&J
Johnson & Johnson
JV
Joint Venture
King
King Pharmaceuticals LLC (formerly King Pharmaceuticals, Inc.)
LDL
low density lipoprotein
LIBOR
London Interbank Offered Rate
Lilly
Eli Lilly & Company
MCO
managed care organization
mCRC
metastatic colorectal cancer
MD&A
Management s Discussion and Analysis of Financial Condition and Results of Operations
Medivation
Medivation LLC (formerly Medivation, Inc.)
Meridian
Meridian Medical Technologies, Inc.
Moody s
Moody s Investors Service
Mylan
Mylan N.V.
NDA
new drug application
NSCLC
non-small cell lung cancer
OPKO
OPKO Health, Inc.
PARP
poly ADP ribose polymerase
PBM
pharmacy benefit manager
Pharmacia
Pharmacia Corporation
PP&E
property, plant & equipment
PsA
psoriatic arthritis
Quarterly Report on Form 10-Q
Quarterly Report on Form 10-Q for the quarterly period ended June 28, 2020
RA
rheumatoid arthritis
RCC
renal cell carcinoma
R&D
research and development
Sandoz
Sandoz, Inc., a division of Novartis AG
SEC
U.S. Securities and Exchange Commission
SI&A
selling, informational and administrative
S&P
Standard and Poor s
TCJA
legislation commonly referred to as the U.S. Tax Cuts and Jobs Act of 2017
Therachon
Therachon Holding AG
UC
ulcerative colitis
U.K.
United Kingdom
U.S.
United States
Valneva
Valneva SE
ViiV
ViiV Healthcare Limited
VBP
Volume-based procurement
WRDM
Worldwide Research, Development and Medical
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED)
Three Months Ended
Six Months Ended
(MILLIONS, EXCEPT PER COMMON SHARE DATA)
June 28,
2020
June 30,
2019
June 28,
2020
June 30,
2019
Revenues
11,801
13,264
23,829
26,382
Costs and expenses:
Cost of sales(a)
2,281
2,576
4,658
5,009
Selling, informational and administrative expenses(a)
3,030
3,511
5,903
6,850
Research and development expenses(a)
2,132
1,842
3,856
3,544
Amortization of intangible assets
905
1,184
1,790
2,367
Restructuring charges and certain acquisition-related costs
362
(115
431
(69
(Gain) on completion of Consumer Healthcare JV transaction
(6
Other (income)/deductions net
(862
126
(641
218
Income from continuing operations before provision/(benefit) for taxes on income
3,953
4,141
7,838
8,463
Provision/(benefit) for taxes on income
519
(915
993
(481
Income from continuing operations
3,434
5,056
6,845
8,945
Discontinued operations net of tax
Net income before allocation to noncontrolling interests
3,434
5,056
6,845
8,945
Less: Net income attributable to noncontrolling interests
10
17
15
Net income attributable to Pfizer Inc.
3,426
5,046
6,828
8,929
Earnings per common share basic:
Income from continuing operations attributable to Pfizer Inc. common shareholders
0.62
0.91
1.23
1.59
Discontinued operations net of tax
Net income attributable to Pfizer Inc. common shareholders
0.62
0.91
1.23
1.59
Earnings per common share diluted:
Income from continuing operations attributable to Pfizer Inc. common shareholders
0.61
0.89
1.22
1.56
Discontinued operations net of tax
Net income attributable to Pfizer Inc. common shareholders
0.61
0.89
1.22
1.56
Weighted-average shares basic
5,554
5,562
5,550
5,598
Weighted-average shares diluted
5,619
5,672
5,616
5,711
(a)
Excludes amortization of intangible assets, except as disclosed in Note 9A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.
Amounts may not add due to rounding.
See Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(UNAUDITED)
Three Months Ended
Six Months Ended
(MILLIONS OF DOLLARS)
June 28,
2020
June 30,
2019
June 28,
2020
June 30,
2019
Net income before allocation to noncontrolling interests
3,434
5,056
6,845
8,945
Foreign currency translation adjustments, net(a)
(242
(485
(1,513
(161
Reclassification adjustments
(242
(485
(1,513
(159
Unrealized holding gains/(losses) on derivative financial instruments, net
213
(176
(288
91
Reclassification adjustments for gains included in net income(b)
(186
(81
(167
(343
27
(256
(455
(252
Unrealized holding gains/(losses) on available-for-sale securities, net
42
(7
(9
33
Reclassification adjustments for losses included in net income(c)
44
26
59
37
87
19
50
70
Benefit plans: actuarial gains/(losses), net
(4
(160
(4
Reclassification adjustments related to amortization
67
60
133
121
Reclassification adjustments related to settlements, net
13
66
Other
68
41
84
18
153
100
122
137
Benefit plans: prior service costs and other, net
(1
(1
Reclassification adjustments related to amortization of prior service costs and other, net
(45
(46
(89
(93
Other
(40
(46
(85
(92
Other comprehensive loss, before tax
(14
(669
(1,882
(296
Tax provision/(benefit) on other comprehensive loss
113
(59
(265
(34
Other comprehensive loss before allocation to noncontrolling interests
(127
(610
(1,617
(262
Comprehensive income before allocation to noncontrolling interests
3,307
4,446
5,227
8,683
Less: Comprehensive income/(loss) attributable to noncontrolling interests
(4
12
13
Comprehensive income attributable to Pfizer Inc.
3,312
4,434
5,222
8,669
(a)
Amounts in the second quarter of 2020 include losses from the weakening of certain major currencies against the U.S. dollar, partially offset by a gain of approximately $380 million pre-tax ($291 million after-tax) related to foreign currency translation adjustments and the impact of our net investment hedging program, both attributable to our equity method investment in the GSK Consumer Healthcare joint venture. Amounts in the first six months of 2020 include a loss of approximately $1.2 billion pre-tax ($902 million after-tax) related to foreign currency translation adjustments and the impact of our net investment hedging program, both attributable to our equity method investment in the GSK Consumer Healthcare joint venture and losses from the weakening of certain major currencies against the U.S. dollar, partially offset by the results of our net investment hedging program. For additional information on the GSK Consumer Healthcare joint venture, see Note 2B. Acquisition, Equity-Method Investment and Licensing Arrangements: Equity-Method Investment.
(b)
Reclassified into Other (income)/deductions net and Cost of sales in the condensed consolidated statements of income. For additional information on amounts reclassified into Other (income)/deductions net and Cost of sales, see Note 7E. Financial Instruments: Derivative Financial Instruments and Hedging Activities.
(c)
Reclassified into Other (income)/deductions net.
Amounts may not add due to rounding.
See Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(MILLIONS OF DOLLARS)
June 28,
2020
December 31,
2019
(Unaudited)
Assets
Cash and cash equivalents
1,801
1,305
Short-term investments
9,581
8,525
Restricted short-term investments(a)
11,412
Trade accounts receivable, less allowance for doubtful accounts: 2020 $525; 2019 $527
9,128
8,724
Inventories
8,564
8,283
Current tax assets
3,426
3,344
Other current assets
2,513
2,622
Total current assets
46,424
32,803
Equity-method investments
15,578
17,133
Long-term investments
3,142
3,014
Property, plant and equipment, less accumulated depreciation: 2020 $16,889; 2019 $16,789
14,113
13,967
Identifiable intangible assets, less accumulated amortization
33,541
35,370
Goodwill
58,449
58,653
Noncurrent deferred tax assets and other noncurrent tax assets
2,360
2,099
Other noncurrent assets
4,327
4,450
Total assets
177,934
167,489
Liabilities and Equity
Short-term borrowings, including current portion of long-term debt: 2020 $1,481; 2019 $1,462
13,084
16,195
Trade accounts payable
3,872
4,220
Dividends payable
2,111
2,104
Income taxes payable
1,445
980
Accrued compensation and related items
2,042
2,720
Other current liabilities
10,168
11,083
Total current liabilities
32,723
37,304
Long-term debt(a)
50,529
35,955
Pension benefit obligations, net
5,344
5,638
Postretirement benefit obligations, net
1,086
1,124
Noncurrent deferred tax liabilities
5,409
5,578
Other taxes payable
11,468
12,126
Other noncurrent liabilities
6,812
6,317
Total liabilities
113,370
104,042
Commitments and Contingencies
Preferred stock
17
Common stock
470
468
Additional paid-in capital
87,886
87,428
Treasury stock
(110,978
(110,801
Retained earnings
100,203
97,670
Accumulated other comprehensive loss
(13,246
(11,640
Total Pfizer Inc. shareholders equity
64,336
63,143
Equity attributable to noncontrolling interests
228
303
Total equity
64,564
63,447
Total liabilities and equity
177,934
167,489
(a)
The balance as of June 28, 2020 reflects the Upjohn Inc. and Upjohn Finance B.V. debt issuances. For additional information see Note 7D. Financial Instruments: Long-Term Debt.